Vilya develops de novo macrocycles through AI-driven computational drug design and synthetic biology. Its platform generates, predicts, and validates novel therapeutic molecules designed from first principles.
Vilya develops de novo macrocycles through AI-driven computational drug design and synthetic biology. Its platform generates, predicts, and validates novel therapeutic molecules designed from first principles.